目的 探讨康妇炎胶囊联合阿奇霉素治疗慢性盆腔炎的临床效果。方法 选取2016年1月—2017年10月温县人民医院收治的134例慢性盆腔炎患者，随机分为对照组和治疗组，每组各67例。对照组口服阿奇霉素片，0.5 g/次，1次/d。治疗组在对照组治疗基础上口服康妇炎胶囊，3粒/次，3次/d。两组均连续治疗21 d。观察两组的临床疗效，比较两组治疗前后盆腔包块直径、症状评分、搏动指数（PI）、收缩期峰值流速（PSV）、阻力指数（RI）、白细胞介素（IL）-1β、IL-10和外周血CD⁴⁺/CD⁸⁺的变化情况。结果 治疗后，对照组和治疗组的总有效率分别为79.10%、92.54%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者盆腔包块直径显著缩小，带下异常评分、腰骶胀痛评分、下腹疼痛评分、总评分、IL-1β均显著降低，PI、PSV、RI值、IL-10、CD⁴⁺/CD⁸⁺较治疗前显著增加，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组盆腔包块直径、带下异常评分、腰骶胀痛评分、下腹疼痛评分、总评分、IL-1β均显著低于对照组，PI、PSV、RI值、IL-10、CD⁴⁺/CD⁸⁺高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 康妇炎胶囊联合阿奇霉素治疗慢性盆腔炎具有较好的临床疗效，可有效改善患者症状，调节卵巢血流动力学状态，纠正机体促炎/抗炎因子失衡，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Kangfuyan Capsules combined with azithromycin in treatment of chronic pelvic inflammation. Methods Patients (134 cases) with chronic pelvic inflammation in Wenxian County People's Hospital from January 2016 to October 2017 were randomly divided into control (67 cases) and treatment (67 cases) groups. Patients in the control group were po administered with Azithromycin Tablets, 0.5 g/time, once daily. Patients in the treatment group were po administered with Kangfuyan Capsules on the basis of the control group,, three grains/time, three times daily. Patients in two groups were treated for 21 d. After treatment, the clinical efficacy was evaluated, and the pelvic cavity diameter, symptom score, PI, PSV, RI, IL-1β, IL-10, and CD⁴⁺/CD⁸⁺ in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 79.10% and 92.54%, and there were differences between two groups (P < 0.05). After treatment, pelvic cavity diameter in two groups were significantly decreased, and abnormal scores, lumbosacral pain scores, lower abdominal pain scores, total scores, and IL-1β were significantly reduced, but PI, PSV, RI, IL-10, CD⁴⁺/CD⁸⁺ were significantly increased, and there were differences in the same group (P < 0.05). After treatment, pelvic cavity diameter, abnormal scores, lumbosacral pain scores, lower abdominal pain scores, total scores, and IL-1β in the treatment group were lower than those in the control group, but PI, PSV, RI, IL-10, CD⁴⁺/CD⁸⁺ were higher than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Kangfuyan Capsules combined with azithromycin has significant clinical effect in treatment of chronic pelvic inflammation, and can effectively improve the symptoms and regulate the hemodynamic state of the ovary, and also can correct the imbalance of pro-inflammatory/anti-inflammatory factors, which has a certain clinical application value.